相关实验视频

Updated: Feb 28, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

通过ERCC8沉默在黑色素瘤中重新利用基化剂:一种新的治疗策略

Silvia Filippi¹, Emma Valeri¹, Valeria Bartolocci¹

¹Unit of Molecular Genetics of Aging, Department of Ecological and Biological Sciences, University of Tuscia, 01100 Viterbo, Italy.

|February 27, 2026

概括

抑制CSA/ERCC8,一种在黑色素瘤中过度表达的蛋白质,可以克服化学抵抗. 沉默CSA增强了对化剂 (如Temozolomide和Dacarbazine) 的敏感性,提供了一个潜在的新治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

黑色素瘤是最致命的皮肤癌,通常会对化疗产生耐药性.
化剂如特莫佐洛米德 (TMZ) 和达卡巴 (DTIC) 在黑色素瘤治疗中有效性有限.
矛盾的是,CSA/ERCC8,一种DNA修复因子,与科凯恩综合征患者的皮肤癌增加无关,这表明它在亡促进中发挥了作用.

研究的目的:

研究CSA/ERCC8在黑色素瘤化学抵抗中的作用.
为了确定CSA抑制是否可以使黑色素瘤细胞对化剂重新敏感.

主要方法:

使用定量实时PCR和西部黑斑来分析CSA/ERCC8表达.
通过使用反感性寡核酸来使CSA/ERCC8沉默.
功能测试评估了细胞活力,细胞亡,细胞循环和药物敏感性 (IC50,Bliss分析).

主要成果:

在黑色素瘤细胞中,CSA/ERCC8显著过度表达.
沉默CSA/ERCC8降低了黑色素瘤细胞的增殖和诱导的亡.
抑制ERCC8增强了黑色素瘤细胞对低剂量TMZ和DTIC的敏感性,同时保留了正常细胞.

结论:

CSA/ERCC8是黑色素瘤化学抵抗的一个关键驱动因素.
准CSA/ERCC8是一种有前途的治疗策略,可以克服对化剂的耐药性.
抑制CSA为耐火性黑色素瘤提供了潜在的救援疗法,需要进一步调查.

关键词:

基因损伤反应 (DDR) 是一种对DNA损伤的反应.针对DNA修复的向.在ERCC8中,ERCC8是ERCC8的成员之一.无意义的寡核酸 (ASO) 是一种反意义的寡核酸 (ASO).化学电阻是一种化学电阻.考凯恩综合征是一种蛋白质A.黑色素瘤是一种黑色素瘤.合成杀伤性合成杀伤性

更多相关视频

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...